Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
As of July 26, 2022, Pluri will begin trading on Nasdaq under the new ticker symbol PLUR, CUSIP number 72942G 104.
- As of July 26, 2022, Pluri will begin trading on Nasdaq under the new ticker symbol PLUR, CUSIP number 72942G 104.
- After nearly two decades as Pluristem, we are proud to expand as Pluri, leveraging our revolutionary technology to increase our market share across multiple verticals.
- Pluris first collaboration, based on its innovative 3D cell-based technology platform, was formed in January 2022 to produce sustainable cultured food with Israeli food giant Tnuva Group.
- Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the companys 3D cell-based technology to additional industries that require effective, mass cell production.